BG
LAB icon

BlackRock Group’s Standard BioTools LAB Stock Holding History

BlackRock Group’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-12,242
Closed -$98K – 2989
2016
Q3 		$98K Buy
12,242
+495
+4% +$4.55K ﹤0.01% 2819
2016
Q2 		$106K Sell
11,747
-165
-1% -$1.55K ﹤0.01% 2780
2016
Q1 		$96K Buy
11,912
+3,833
+47% +$27.6K ﹤0.01% 2775
2015
Q4 		$87K Sell
8,079
-220
-3% -$2.16K ﹤0.01% 2722
2015
Q3 		$67K Buy
8,299
+1,316
+19% +$20.7K ﹤0.01% 2795
2015
Q2 		$169K Buy
6,983
+1,375
+25% +$43.4K ﹤0.01% 2625
2015
Q1 		$236K Buy
5,608
+2,229
+66% +$88.1K ﹤0.01% 2444
2014
Q4 		$114K Buy
3,379
+126
+4% +$3.57K ﹤0.01% 2645
2014
Q3 		$80K Sell
3,253
-38
-1% -$1.07K ﹤0.01% 2619
2014
Q2 		$97K Sell
3,291
-3,205
-49% -$103K ﹤0.01% 2605
2014
Q1 		$286K Buy
6,496
+4,602
+243% +$202K ﹤0.01% 2379
2013
Q4 		$73K Buy
+1,894
New +$55.8K ﹤0.01% 2514

Other funds holding LAB

LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Group's LAB Position: Q4 2016 in Review

BlackRock Group sold out of Standard BioTools (LAB) in Q4 2016, closing a stake of 12,242 shares — an estimated $98K sold.

BlackRock Group first reported a position in LAB in Q4 2013 and held it in 12 quarters. The position peaked at $286K in Q1 2014. 83 funds tracked by Wall St. Rank hold LAB as of Q4 2016.

  • BlackRock Group reported no remaining Standard BioTools position as of Q4 2016 after selling out during the quarter.
  • BlackRock Group sold 12,242 Standard BioTools shares in Q4 2016, an estimated $98K.
  • BlackRock Group first reported a position in Standard BioTools in Q4 2013 and held it in 12 quarters.
  • BlackRock Group's Standard BioTools position peaked at $286K in Q1 2014.
  • 83 funds tracked by Wall St. Rank held Standard BioTools as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.